Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05537402 · ClinicalTrials.gov registry record · Phase 2
LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT05537402: Clinical Trial Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
NCT05537402 is a Phase 2 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05537402, a Phase 2 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this research study is to compare the effectiveness and safety of two standard of care treatments in people who have been diagnosed with hepatocellular carcinoma (HCC).This research study is being done to compare atezolizumab/bevacizumab to locoregional therapy with either transarterial chemoembolization (TACE) or transarterial radioembolization (TARE).
Primary Outcome
Evaluate the efficacy of atezolizumab and bevacizumab compared to TACE or TARE as measured by progression-free survival after randomization. PFS is defined as time from randomization to death from any cause or radiologic tumor progression, according to investigator assessment per mRECIST (modified Response Evaluation Criteria in Solid Tumors ).
Interventions
- DRUG Atezolizumab and bevacizumab
- RADIATION transarterial chemoembolization (TACE) or transarterial radioembolization (TARE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-09-27 |
| Est. Completion | 2025-06-06 |
| Phase | Phase 2 |
Why NCT05537402 stopped before completion
NCT05537402 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab and bevacizumab is the first listed.
NCT05537402 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05537402 about?
NCT05537402 is a clinical study titled "LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC". The purpose of this research study is to compare the effectiveness and safety of two standard of care treatments in people who have been diagnosed with hepatocellular carcinoma (HCC).This research study is being done to compare atezolizumab/bevacizumab to locoregional therapy with either transarteri...
What is the current status of trial NCT05537402?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2023-09-27. Estimated completion is 2025-06-06.
What interventions are being tested in trial NCT05537402?
The interventions under investigation include: Atezolizumab and bevacizumab (DRUG), transarterial chemoembolization (TACE) or transarterial radioembolization (TARE (RADIATION).
Who is sponsoring clinical trial NCT05537402?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05537402's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI